{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Genelux Corporation"},"Symbol":{"label":"Symbol","value":"GNLX"},"Address":{"label":"Address","value":"2625 TOWNSGATE ROAD,SUITE 230, WESTLAKE VILLAGE, California, 91361, United States"},"Phone":{"label":"Phone","value":"(815) 721-4912"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California."},"CompanyUrl":{"label":"Company Url","value":"https://www.genelux.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Joseph Cappello","title":"Chief Technical Officer"},{"name":"Paul Scigalla","title":"Chief Medical Officer"},{"name":"Thomas D. Zindrick","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}